ERR2598165
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 4
- umap1_2d
- -2.189561089
- umap2_2d
- -1.089454987
- umap1_3d
- -4.167645081
- umap2_3d
- 3.424650175
- umap3_3d
- -1.560082126
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.700
- E2F_TARGETS+0.690
- MYC_TARGETS_V1+0.660
- G2M_CHECKPOINT+0.600
- MTORC1_SIGNALING+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.420
- DNA_REPAIR+0.330
- WNT_BETA_CATENIN_SIGNALING+0.310
- MITOTIC_SPINDLE+0.300
- ANDROGEN_RESPONSE+0.280
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.380
- INTERFERON_ALPHA_RESPONSE-0.300
- PANCREAS_BETA_CELLS-0.300
- COMPLEMENT-0.170
- TNFA_SIGNALING_VIA_NFKB-0.170
- KRAS_SIGNALING_UP-0.160
- KRAS_SIGNALING_DN-0.150
- OXIDATIVE_PHOSPHORYLATION-0.150
- BILE_ACID_METABOLISM-0.140
- INTERFERON_GAMMA_RESPONSE-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598181 | fetal | fetal | 0.959 |
| 2 | ERR2598164 | fetal | fetal | 0.958 |
| 3 | ERR2598180 | fetal | fetal | 0.954 |
| 4 | ERR2598166 | fetal | fetal | 0.938 |
| 5 | ERR2598170 | fetal | fetal | 0.930 |
| 6 | ERR2598184 | fetal | fetal | 0.874 |
| 7 | 67719D37-8CC2-42B5-AF44-6D5AC258FDB1 | — | — | 0.867 |
| 8 | ERR2598169 | fetal | fetal | 0.864 |
| 9 | ERR2598171 | fetal | fetal | 0.852 |
| 10 | MDT-AP-0535 | Med | Medulloblastoma | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.700 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.690 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.660 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.420 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |